ALK (F1174S)
Sign in to save this workspaceALK · Variant type: point · HGVS: p.F1174S
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Gilteritinib | 99.8% | 0.2% | 88.97 |
| 2 | Lorlatinib | 99.8% | 0.3% | 97.24 |
| 3 | Ceritinib | 99.6% | 0.4% | 95.44 |
| 4 | Alectinib | 99.1% | 0.9% | 95.49 |
| 5 | Entrectinib | 99.0% | 1.0% | 93.69 |
| 6 | Repotrectinib | 98.8% | 1.2% | 84.21 |
| 7 | Crizotinib | 98.5% | 1.5% | 91.39 |
| 8 | Brigatinib | 97.7% | 2.3% | 82.96 |
| 9 | Sunitinib | 91.6% | 8.4% | 91.73 |
| 10 | Nintedanib | 87.6% | 12.4% | 90.23 |
| 11 | Osimertinib | 82.2% | 17.9% | 97.24 |
| 12 | Bosutinib | 79.1% | 20.9% | 87.22 |
| 13 | Pacritinib | 73.2% | 26.8% | 88.64 |
| 14 | Pralsetinib | 72.8% | 27.2% | 93.43 |
| 15 | Alpelisib | 71.0% | 29.0% | 97.22 |
| 16 | Ruxolitinib | 69.0% | 31.0% | 98.25 |
| 17 | Baricitinib | 56.1% | 43.9% | 97.99 |
| 18 | Darovasertib | 51.1% | 48.9% | 96.99 |
| 19 | Defactinib | 49.2% | 50.8% | 92.68 |
| 20 | Erlotinib | 47.2% | 52.8% | 99.75 |
| 21 | Vandetanib | 44.9% | 55.1% | 95.74 |
| 22 | Afatinib | 44.7% | 55.3% | 98.50 |
| 23 | Fedratinib | 44.5% | 55.5% | 96.21 |
| 24 | Lazertinib | 43.0% | 57.0% | 97.47 |
| 25 | Neratinib | 40.8% | 59.2% | 93.18 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Gilteritinib | 99.8% | 99.5% | +0.3% |
| Lorlatinib | 99.8% | 97.2% | +2.5% |
| Ceritinib | 99.6% | 98.3% | +1.4% |
| Alectinib | 99.1% | 98.6% | +0.5% |
| Entrectinib | 99.0% | 98.8% | +0.2% |
| Repotrectinib | 98.8% | 99.4% | -0.6% |
| Crizotinib | 98.5% | 97.7% | +0.7% |
| Brigatinib | 97.7% | 99.2% | -1.6% |
| Sunitinib | 91.6% | 87.7% | +3.9% |
| Nintedanib | 87.6% | 84.9% | +2.7% |
| Osimertinib | 82.2% | 80.5% | +1.6% |
| Bosutinib | 79.1% | 75.1% | +4.0% |
| Pacritinib | 73.2% | 55.3% | +17.9% |
| Pralsetinib | 72.8% | 82.6% | -9.7% |
| Alpelisib | 71.0% | 80.7% | -9.7% |
| Ruxolitinib | 69.0% | 52.1% | +16.9% |
| Baricitinib | 56.1% | 46.4% | +9.8% |
| Darovasertib | 51.1% | — | — |
| Defactinib | 49.2% | — | — |
| Erlotinib | 47.2% | — | — |
| Vandetanib | 44.9% | — | — |
| Afatinib | 44.7% | — | — |
| Fedratinib | 44.5% | — | — |
| Lazertinib | 43.0% | 46.3% | -3.3% |
| Neratinib | 40.8% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| neuroblastoma_autonomic_ganglia | Brain/CNS | ref |
| carcinoma_endometrium | Uterus | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 16.7ms